Krakowski Szpital Specjalistyczny im Jana Pawła II

At Krakowski Szpital Specjalistyczny im Jana Pawła II, clinical research in cardiology focuses on a wide range of cardiovascular diseases, especially acute myocardial infarction, heart failure, atrial fibrillation, and atherosclerotic cardiovascular disease. These studies are designed to test new treatments, improve prevention, and better reduce the risk of serious cardiac events.

• New therapies for myocardial infarction and recovery after a heart attack
• Treatment strategies for heart failure, including reduced and preserved ejection fraction
• Research on atrial fibrillation, bleeding risk, and stroke prevention
• Studies aimed at lowering cardiovascular event rates in high-risk patients

The site also explores approaches for myocarditis, cardiomyopathy, and myocardial injury after noncardiac surgery, reflecting a strong interest in improving both treatment effectiveness and long-term outcomes.

This research center has a major focus on pulmonary arterial hypertension and related respiratory tract diseases. Trials also include pulmonary hypertension linked to heart failure or interstitial lung disease, with the goal of improving symptoms, exercise capacity, and overall disease control.

• Studies of new treatments for pulmonary arterial hypertension
• Research in pulmonary hypertension related to left heart disease and lung disease
• Trials evaluating better control of breathlessness and physical function
• Long-term safety studies for therapies used in PAH

Several projects at the site examine whether emerging therapies can improve pulmonary vascular resistance and day-to-day functioning in people living with these complex conditions.

Clinical trials in oncology at this site are strongly centered on non-small cell lung cancer, with additional work in small-cell lung cancer and selected other cancers such as esophageal cancer and breast cancer. The research is aimed at improving survival, slowing disease progression, and matching treatment to tumor features.

• Testing new approaches for advanced or metastatic non-small cell lung cancer
• Studies in resectable lung cancer to improve outcomes before and after surgery
• Research on targeted treatment for mutation-defined cancers, including KRAS G12C and RET fusion disease
• Trials combining immunotherapy with other cancer treatments

These studies reflect a broad effort to refine cancer therapy through more personalized and effective treatment options.

The site also investigates several rare diseases and neuromuscular disorders, including Marfan syndrome, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Fabry disease. These trials are intended to support better disease control, symptom relief, and long-term protection of affected organs.

• Research on heritable thoracic aortic disease in people with Marfan-type conditions
• Studies of new options for generalized myasthenia gravis
• Trials in CIDP and related immune-mediated nerve disease
• Work on rare inherited disorders such as Fabry disease and amyloidosis

These programs aim to improve both diagnosis and treatment effectiveness in conditions where specialized care is especially important.

Clinical research in infectious diseases at this health care site includes studies in chronic hepatitis B, COVID-19, pneumococcal disease, and meningococcal infection. The main goal is to improve prevention, strengthen treatment response, and support safer care for vulnerable groups.

• Trials focused on better control of chronic hepatitis B
• Studies evaluating treatments for COVID-19 in younger patients
• Prevention research for pneumococcal and meningococcal disease
• Public health-oriented work on infection risk reduction

These studies show an interest in both therapeutic innovation and disease prevention across important infectious conditions.

Research at the site also covers nutritional and metabolic diseases, digestive system diseases, and related organ complications. Trials include severe hypertriglyceridemia, kidney injury linked to surgery, and conditions after total gastrectomy, with the aim of improving management and reducing complications.

• Studies targeting severe hypertriglyceridemia and lipid control
• Research to prevent acute kidney injury after cardiac surgery
• Clinical work on recovery and outcomes after gastrectomy
• Investigation of broader metabolic and systemic inflammatory risk

Across these areas, the focus is on improving treatment effectiveness and supporting safer long-term care for patients with complex, multi-system disease.